Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 68

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 68
---
 informed Mr. Endicott that the proposed purchase price of $27.00 per share was insufficient and
that the Board required a purchase price of at least $29.00 per share of STAAR common stock in order to continue discussions.

On
July 12, 2025, Mr. Endicott called Mr. Farrell and indicated that Alcon was unwilling to proceed at a purchase price of $29.00 per share, but that Alcon would be willing to offer $28.00 per share, subject to completing diligence. On
July 11, 2025, the last trading day prior to July 12, 2025, the trading price of STAAR common stock closed at $17.38 per share, and therefore the proposed price of $28.00 per share represented an approximately 61% premium to such closing
price.

Later on July 12, 2025, Mr. Farrell informed the Board of Alcon’s proposed purchase price of $28.00 per share and
discussed appropriate next steps with the Chair of the Board. Based on those communications as well as prior guidance from the Board, Mr. Farrell informed Alcon that the Board would consider proceeding with diligence at $28.00 per share of
STAAR common stock, provided that the definitive documentation reflected terms acceptable to the Board.

Later on the evening of
July 12, 2025, Mr. Endicott sent Mr. Farrell a non-binding offer letter setting forth certain terms under which Alcon would acquire STAAR (the “July 12 Offer”). The July 12
Offer indicated that Alcon would acquire all of the outstanding shares of STAAR common stock for $28.00 per share, and that Alcon believed it could be in a position to announce the transaction by August 4, 2025.

On July 14, 2025, Mr. Farrell contacted representatives of Broadwood to request an in-person
meeting.

On July 15, 2025, following the execution of a confidentiality agreement between STAAR and Broadwood (which did not contain
a standstill obligation), Mr. Farrell and representatives of Broadwood met in person to discuss STAAR’s financial performance, prospects and perspectives on valuation. During the meeting,

-42-

Mr. Farrell did not specifically identify Alcon by name or details of the potential transaction with Alcon, but inquired if Broadwood would be supportive of an acquisition of STAAR.
Representatives of Broadwood indicated that they likely would